| Metric | Q1'26 | Q2'26 | Change |
|---|---|---|---|
| Adjusted EPS | $1.06 (Q1'26) | $2.40 (Q2'26) | +126% QoQ, driven by price and midstream timing |
| Reported EPS | $3.13, inflated by OxyChem sale gain | $2.75, inflated by mark-to-market + dilution gain | Two straight quarters of large one-time gains distorting GAAP EPS |
| Free cash flow (before working capital) | $1.7B | ~$3.0B, highest since Q3'22 | Nearly doubled, but metric excludes working capital by definition both quarters |
| Production | 1.43M BOE/d, exceeded high end of guidance | 1.43M BOE/d, beat guidance by 23,000 BOE/d | Flat but another beat vs guide |
| Domestic LOE ($/BOE) | $7.85, 5% improvement vs Q1 guidance | $7.80, 6% better than guide | Continued outperformance |
| Midstream adjusted earnings | ~$400M above midpoint of guidance | $960M, record, >2x midpoint | Absolute record but explicitly timing-driven, guided down next quarter |
| Principal debt | $13.3B, below $14.3B target | $11.8B, lowest since Q2'19 | -$1.5B QoQ, ahead of $10B milestone |
| Go-forward annual interest run rate | $845M | $760M | -$85M QoQ, ~$630M lower than 2025 |
| Unrestricted cash | $3.8B | $4.2B; net principal debt now $7.6B | +$0.4B, building toward 2029 preferred redemption |
| FY26 production guidance | Midpoint 1.44M BOE/d | Raised (no new midpoint given) | Raised again, absolute language without new midpoint disclosed |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.